Bone Health and Bone-Targeted Therapies for Nonmetastatic PCa.

[pjoshea13]

New meta-analysis below.

"Bisphosphonates were effective in increasing BMD, but no trial was sufficiently powered to detect reduction in fractures. Denosumab improved BMD and reduced the incidence of new radiographic vertebral fractures in 1 high-quality trial. No trials compared calcium or vitamin D versus placebo."

& no trials gave low-dose estradiol [E2] patches to men with E2 < 20pg/mL.

IMO it is criminal to ignore E2 deficiency, which can be a direct result of ADT - & E2 replacement as the solution. There is a significant risk of necosis of the jaw with bisphosphonate use by men with PCa.

-Patrick

annals.org/aim/article/2647...

Bone Health and Bone-Targeted Therapies for Nonmetastatic Prostate Cancer: A Systematic Review and Meta-analysis

Shabbir M.H. Alibhai, MD, MSc (*); Katherine Zukotynski, MD (*); Cindy Walker-Dilks, MLS; Urban Emmenegger, MD; Antonio Finelli, MD, MSc; Scott C. Morgan, MD, MSc; Sebastién J. Hotte, MD, MSc; George A. Tomlinson, PhD; Eric Winquist, MD, MSc

Abstract

Background:

Bone health is a significant concern in men with prostate cancer.

Purpose:

To evaluate the effectiveness of drug, supplement, and lifestyle interventions aimed at preventing fracture, improving bone mineral density (BMD), or preventing or delaying osteoporosis in men with nonmetastatic prostate cancer.

Data Sources:

Ovid MEDLINE (1946 to 19 January 2017), EMBASE (1980 to 18 January 2017), and the Cochrane Database of Systematic Reviews (19 January 2017).

Study Selection:

Randomized trials and systematic reviews of trials that were published in English; involved men with nonmetastatic prostate cancer; and compared bone-targeted therapies with placebo, usual care, or other active treatments.

Data Extraction:

Two reviewers independently extracted study characteristics and assessed study risk of bias for each outcome.

Data Synthesis:

Two systematic reviews and 28 reports of 27 trials met inclusion criteria. All trials focused on men with nonmetastatic prostate cancer who were initiating or continuing androgen deprivation therapy (ADT). Bisphosphonates were effective in increasing BMD, but no trial was sufficiently powered to detect reduction in fractures. Denosumab improved BMD and reduced the incidence of new radiographic vertebral fractures in 1 high-quality trial. No trials compared calcium or vitamin D versus placebo. Three lifestyle intervention trials did not show a statistically significant difference in change in BMD between exercise and usual care.

Limitations:

Most trials were of moderate quality. Only 2 randomized controlled trials were designed to examine fracture outcomes. Potential harms of treatments were not evaluated.

Conclusion:

Both bisphosphonates and denosumab improve BMD in men with nonmetastatic prostate cancer who are receiving ADT. Denosumab also reduces risk for radiographic vertebral fractures, based on 1 trial. More trials studying fracture outcomes are needed in this population.

Primary Funding Source:

Program in Evidence-Based Care.

[rococo]

Keeping bones strong and smooth as silk and get bone density test and script for biophosinates , fosamax, denosamab, zometa

.